The IPO Buzz
IPO Calendar
Last Week's IPO Traffic
2015 Pricings
Last 100 IPOs
Last 12 Months
IPOs by Managers
By Industry
Secondary Offerings
IPO Pipeline
SCOOP Ratings
IPOs Recently Filed
IPOs by Managers
By Industry
Secondary Offerings
SCOOP Track Record From 2000 to Present
IPO Traffic by Week
IPO Index
MediWound Ltd. 
General Information
Business: We are a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. Our innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency, or the EMA, in December 2012 for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid, which is based on our patented proteolytic enzyme technology, represents a new paradigm in burn care management, and our clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. We launched NexoBrid in December 2013 in the European Union through our wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units. We also plan to initiate a Phase 3 pivotal study in the United States in the first half of 2014 to support a Biologics License Application, or BLA, submission to the United States Food and Drug Administration, or FDA. We manufacture NexoBrid in our state-of-the-art, EMA-certified, cGMP-compliant, sterile pharmaceutical products manufacturing facility at our headquarters in Yavne, Israel.
Employees: 43 Founded: 2000
Contact Information
Address: 42 Hayarkon Street, Yavne 8122745, IL
Phone: 972-8-932-4010
Web Address:
View Prospectus: MediWound Ltd.
Financial Information
Market Cap: $ 306.0 mil
Revenues: $ 0.0 mil (last 12 months)
Net Income: $ -15.4 mil (last 12 months)
IPO Profile
Symbol: MDWD
Shares (millions): 5.0
Price Range: $14.00 - $14.00
Est.$ Volume $ 70.0 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ BMO Capital Markets
Co Managers Oppenheimer
Expected to Trade 3/20/2014
Status Priced
SCOOP RATING Available only to Subscribers
RATING CHANGE Available only to Subscribers

© 2015 All rights reserved.